Gaxos.ai Inc. (GXAI)
After hours:
| Previous close | 4.5200 |
| Open | 4.4050 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 4.3401 - 4.6599 |
| 52-week range | 2.1720 - 19.2000 |
| Volume | |
| Avg. volume | 1,010,229 |
| Market cap | 5.064M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireGaxos Health Expands Medical Advisory Board
Roseland, NJ, April 25, 2024 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. ("Gaxos" or the "Company"), a company developing artificial intelligence applications across various sectors, today announced that Gaxos Health has expanded its Medical Advisory Board with the appointment of Dr. Eric Margolis and Dr. Jeff Pavell. “The addition of top medical talent to our Medical Advisory Board reflects our continued commitment to pursuing a best-in-class solution for Gaxos Health,” said Vadim Mats, CEO of Gaxos.AI.
GlobeNewswireGaxos.ai Regains Compliance with Nasdaq Listing Requirements
Roseland, NJ, March 26, 2024 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. (NASDAQ: GXAI), (“Gaxos” or the “Company”), a company developing artificial intelligence applications across various sectors, announced today that it received written notice from the NASDAQ Stock Market LLC (NASDAQ) on March 22, 2024, informing the Company that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on the NASDAQ Capital Market. On July 10, 2023, NA
GlobeNewswireGaxos.ai Inc. Announces Closing of $3.5 Million Private Placement Priced At-The-Market under Nasdaq Rules
Roseland, NJ, March 15, 2024 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. (NASDAQ: GXAI), (“Gaxos” or the “Company”), a company developing artificial intelligence applications across various sectors, announced today that it has closed its previously announced private placement for the purchase and sale of 628,367 shares of common stock (or pre-funded warrant in lieu thereof), series A warrants to purchase up to 628,367 shares of common stock and short-term series B warrants to purchase up to 628,367 shares
